N2OFF shares surge 20.45% intraday after rebranding to Nexentis Technologies, shifting focus to AI-driven mitochondrial biotech.

N2OFF surged 20.45% intraday following its announcement of a corporate rebranding to Nexentis Technologies, effective February 26, 2026. The rebranding reflects a strategic pivot from cleantech to an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. Central to the shift is the integration of MitoCareX, a wholly-owned subsidiary with a proprietary MITOLINE™ discovery engine targeting the mitochondrial SLC25 carrier family. The company emphasized its focus on building a pipeline of first-in-class small-molecule programs in a market projected to exceed $120 billion by 2030, while retaining solar energy assets as non-core holdings. The rebranding, coupled with recent in vitro validation of MITOLINE-powered compounds showing anti-inflammatory potential, underscored renewed strategic clarity and R&D alignment, likely driving investor optimism.